Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome

Abstract Abstract 5042 Objective To investigate the expression of dlk1 gene (delta-like 1) in the bone marrow cells of patients with Myelodysplastic syndrome (MDS), and explore the molecular marker for early diagnosis of MDS. Methods The expression of dlk1 mRNA in the bone marrow cells of cases with MDS, AML and normal controls were measured by RT-PCR, aiming to search for the cytogenetic marker of MDS malignant clone. Results The expression of dlk1 mRNA in bone marrow cells of MDS patients (0.7342±0.3652) was significantly higher than that of normal controls (0.4801±0.1759) (P<0.05), and was significantly positively correlated with the proportion of bone marrow blasts(r=0.467,P<0.05). The expression of dlk1 mRNA significantly increased as the subtype of MDS advanced (P<0.05). Patients with abnormal karyotypes displayed significantly higher expression of dlk1 mRNA (0.9007±0.4334) than those with normal karyotypes (0.6411±0.2630) (P<0.05). Patients with higher expression of dlk1(≥0.8) presented significantly higher malignant clone burden (0.4134±0.3999) than those with lower expression (<0.8) of dlk1 (0.1517±0.3109) (P<0.05). Conclusion dlk1 gene was highly expressed in MDS patients, which increased as the subtype of MDS advanced. The expression of dlk1 mRNA was significantly positively correlated with the proportion of bone marrow blasts. High expression of dlk1 gene suggests high malignant clone burden of MDS. Disclosures: No relevant conflicts of interest to declare.

Download Full-text

Faculty Opinions recommendation of Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1168446.630630 ◽

2009 ◽

Author(s):

Antonio Risitano ◽

Fabiana Perna

Keyword(s):

Bone Marrow ◽

Acute Myeloid Leukemia ◽

Myelodysplastic Syndrome ◽

Myeloid Leukemia ◽

Receptor Agonist ◽

Bone Marrow Cells ◽

Thrombopoietin Receptor ◽

Thrombopoietin Receptor Agonist ◽

Acute Myeloid ◽

Marrow Cells

Download Full-text

Immune signatures of bone marrow cells can independently predict prognosis in patients with myelodysplastic syndrome

British Journal of Haematology ◽

10.1111/bjh.17837 ◽

2021 ◽

Author(s):

Yu‐Hung Wang ◽

Chien‐Chin Lin ◽

Chi‐Yuan Yao ◽

Chia‐Lang Hsu ◽

Cheng‐Hong Tsai ◽

...

Keyword(s):

Bone Marrow ◽

Myelodysplastic Syndrome ◽

Bone Marrow Cells ◽

Immune Signatures ◽

Marrow Cells

Download Full-text

An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups

International Journal of Laboratory Hematology ◽

10.1111/ijlh.12860 ◽

2018 ◽

Vol 40 (5) ◽

pp. 549-555 ◽

Cited By ~ 2

Author(s):

T.-H. Chen-Liang ◽

A. M. Casado-Prieto ◽

V. Campos-Rodríguez ◽

A. M. Hurtado ◽

M. L. Amigo ◽

...

Keyword(s):

Bone Marrow ◽

Myelodysplastic Syndrome ◽

Bone Marrow Cells ◽

Marrow Cells

Download Full-text

Myeloproliferative disease and myelodysplastic syndrome induced by transplantation of bone marrow cells expressing mutant p53

Leukemia ◽

10.1038/sj.leu.2400782 ◽

1997 ◽

Vol 11 (10) ◽

pp. 1641-1649 ◽

Cited By ~ 4

Author(s):

Y Shounan ◽

K MacKenzie ◽

A Dolnikov ◽

M Miller ◽

G Symonds

Keyword(s):

Bone Marrow ◽

Myelodysplastic Syndrome ◽

Bone Marrow Cells ◽

Mutant P53 ◽

Myeloproliferative Disease ◽

Marrow Cells

Download Full-text

Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome

Blood ◽

10.1182/blood-2004-05-2017 ◽

2005 ◽

Vol 106 (3) ◽

pp. 841-851 ◽

Cited By ~ 123

Author(s):

Elaine M. Sloand ◽

Lori Mainwaring ◽

Monika Fuhrer ◽

Shakti Ramkissoon ◽

Antonio M. Risitano ◽

...

Keyword(s):

Bone Marrow ◽

T Cells ◽

T Cell ◽

Cell Growth ◽

Myelodysplastic Syndrome ◽

Bone Marrow Cells ◽

Bone Marrow Failure ◽

Cell Contact ◽

Trisomy 8 ◽

Marrow Cells

AbstractClinical observations and experimental evidence link bone marrow failure in myelodysplastic syndrome (MDS) with a T cell–dominated autoimmune process. Immunosuppressive therapy is effective in improving cytopenias in selected patients. Trisomy 8 is a frequent cytogenetic abnormality in bone marrow cells in patients with MDS, and its presence has been associated anecdotally with good response to immunotherapy. We studied 34 patients with trisomy 8 in bone marrow cells, some of whom were undergoing treatment with antithymocyte globulin (ATG). All had significant CD8+ T-cell expansions of one or more T-cell receptor (TCR) Vβ subfamilies, as measured by flow cytometry; expanded subfamilies showed CDR3 skewing by spectratyping. Sorted T cells of the expanded Vβ subfamilies, but not of the remaining subfamilies, inhibited trisomy 8 cell growth in short-term hematopoietic culture. The negative effects of Vβ-expanded T cells were inhibited by major histocompatibility complex (MHC) class 1 monoclonal antibody (mAb) and Fas antagonist and required direct cell-to-cell contact. Sixty-seven percent of patients who had de novo MDS with trisomy 8 as the sole karyotypic abnormality responded to ATG with durable reversal of cytopenias and restoration of transfusion independence, with stable increase in the proportion of trisomy 8 bone marrow cells and normalization of the T-cell repertoire. An increased number of T cells with apparent specificity for trisomy 8 cells is consistent with an autoimmune pathophysiology in trisomy 8 MDS.

Download Full-text